HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Chronobiotic effects of the melatonin agonist LY 156735 following a simulated 9h time shift: results of a placebo-controlled trial.

AbstractINTRODUCTION:
The melatonin agonist LY 156735 (LY) is a new investigational drug under development to treat circadian rhythm disorders. The present study assessed the efficacy of LY to alleviate the symptoms of shift lag and to enhance readaptation of desynchronized circadian rhythms to a new time zone.
SUBJECTS AND METHODS:
Eight healthy male volunteers of age 25-35 yr participated in three identical trials of 13d duration in a temporal isolation unit separated by washout intervals. A high dose (HD) of 5 mg and a low dose (LD) of 0.5 mg of LY and placebo (PL) were administered double-blinded in a three-period cross-over design. Each trial consisted of an adaptation period, a pre-shift period for baseline measurements, a simulated 9h phase-advance shift, and a post-shift period for follow-up. The time shift was performed at 23:00h of day 6 by advancing the laboratory time to 08:00h of day 7. Double-blind study medication was administered at 14:30h on day 6, and at 22:30h on days 7-10. Subjective ratings of jet lag, alertness, tenseness, and daytime fatigue were assessed using visual analog scales (VAS) and standardized questionnaires. The objective markers of readaptation included core body temperature, wrist actigraphy, cortisol and electrolyte excretion, and a battery of computerized performance tests.
RESULTS:
HD but not LD enhanced the readaptation speed of all physiological rhythms investigated, as demonstrated by a significantly faster movement of acrophases towards the post-shift target time. HD (p = 0.05) significantly blunted the post-shift deterioration of performance in those tests that were sensitive to shift lag. Parameters of subjective well-being were not significantly affected by either dose.
CONCLUSION:
This pilot study demonstrates the chronobiotic efficacy of LY when taken at a dose of 5 mg/d.
AuthorsThomas Nickelsen, Alexander Samel, Martin Vejvoda, Juergen Wenzel, Brian Smith, Rupert Gerzer
JournalChronobiology international (Chronobiol Int) Vol. 19 Issue 5 Pg. 915-36 (Sep 2002) ISSN: 0742-0528 [Print] England
PMID12405554 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Indoles
  • LY 156735
  • Melatonin
  • Hydrocortisone
Topics
  • Adaptation, Physiological
  • Adult
  • Body Temperature (drug effects)
  • Circadian Rhythm (drug effects)
  • Cross-Over Studies
  • Double-Blind Method
  • Humans
  • Hydrocortisone (urine)
  • Indoles (pharmacology)
  • Jet Lag Syndrome (drug therapy, physiopathology, psychology)
  • Male
  • Melatonin (agonists, analogs & derivatives, pharmacology)
  • Motor Activity (drug effects)
  • Psychomotor Performance (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: